In-licencing

When appropriate, Advicenne in-licences selected products to strengthen our product portfolio and/or to answer KOLs demand on specific medical needs.

Out-licencing

In 2016, the Company sold ADV6209, an oral paediatric anaesthetic for moderate sedation to the Swiss company Primex Pharmaceuticals.
Press Release

Academic and scientific

Given Advicenne’s desire to improve the treatment of orphan or neglected diseases and to meet the high expectations of patients, we are always open to academic and scientific collaborations to allow us to access new perspectives and to share our knowledge.

European Projects

KIEKIDS is a European project financed by the European Commission to develop a new anti-epileptic for the treatment of black-out in children.